British Journal of Haematology · 2018 · 27 citations · 29 references
MedicineOncologyPharmacotherapyChemotherapyHematologic OncologyMedical OncologyChemotherapy In Hematologic MalignanciesHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyHematopoietic Stem Cell Transplant PharmacotherapyRelapsed DiseaseTherapy Response AssessmentHodgkin Lymphoma TherapyLymphoma RelapseLymphoma Treatment ResponseMultiagent ChemotherapyPhase Iv Clinical TrialsPhase Iv TrialsRefractory Hodgkin LymphomaRelapsed Hodgkin Lymphoma
Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable for stem cell transplant (SCT) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1·8 mg/kg intravenously once every 3 weeks) in 60 patients (aged ≥18 years) with CD30-positive relapsed/refractory HL, a history of ≥1 prior systemic chemotherapy regimen, who were considered unsuitable for SCT/multi-agent chemotherapy. Primary endpoint was overall response rate (ORR) per independent review facility (IRF). Secondary endpoints included duration of response (DOR), progression-free survival (PFS) per IRF, overall survival (OS), proportion proceeding to SCT and safety. The ORR was 50%, with 12% CR; 47% proceeded to SCT. Median DOR was 4·6 months and median duration of CR was 6·1 months. After a median follow-up of 6·9 and 16·6 months, median PFS and OS were 4·8 months (95% confidence interval, 3·0-5·3) and not reached, respectively; estimated OS rate was 86% at 12 months. Most common adverse events (≥10%) were peripheral neuropathy (35%), pyrexia (18%), diarrhoea and neutropenia (each 10%). Brentuximab vedotin showed notable activity with a safety profile consistent with known toxicities, and may act as a bridge to SCT, enabling high-risk patients who achieve suboptimal response to frontline/salvage chemotherapy/radiotherapy to receive potentially curative SCT.
29
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17